You are here: Industry Insights > Ultragenyx

News List

n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases americanpharmaceuticalreview
April 07, 2021
n-Lorem Foundation announced a new partnership with Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases.
Novartis Buys Rare Drug Voucher for $130M From Ultragenyx biospace
December 20, 2017
Novartis picked up a priority review voucher in a $130 million deal with California-based Ultragenyx Pharmaceutical Inc.The PRV is for rare pediatric diseases.
M&As this week: Catalent, Ultragenyx Pharmaceutical pharmaceufical-technology
September 25, 2017
The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors.
Phase 3 fail prompts Ultragenyx to can muscle disease drug fiercebiotech
August 24, 2017
A phase 3 fail wiped more than 10% off Ultragenyx's share price.
Ultragenyx stumbles in P3 trial for severe muscle disease pharmafile
August 23, 2017
Ultragenyx has revealed results from a Phase 3 trial into the treatment of GNE myopathy showed that its compound did not successfully meet the primary or secondary endpoints of the study.